| SWK |
Report |
Adjusted EPS |
BEAT |
pred ~$1.25 vs. cons $1.21 |
MEDIUM |
| SWK |
Report |
Net sales |
IN-LINE |
pred ~$3.96B vs. cons $3.962B |
MEDIUM |
| SWK |
Report |
Organic growth |
MISS |
pred ~2.0% vs. cons 2.19% |
MEDIUM |
| SWK |
Guide |
Adjusted EPS (FY2026) |
LOWER |
guide midpoint ~$5.30 vs. cons $5.37 |
MEDIUM |
| SWK |
Guide |
Organic growth (FY2026) |
BETTER |
guide ~2.0% vs. cons 1.79% |
MEDIUM |
| SWK |
Guide |
Free cash flow (FY2026) |
LOWER |
guide midpoint ~$600M vs. cons $729M |
MEDIUM |
| SWK |
Guide |
Adjusted EPS (Q3 2026) |
UNCHANGED |
guide ~$1.65 vs. cons $1.65 |
LOW |
| SWK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-5.0% |
— |
LOW |
| SWK |
Return |
5-day cumulative residual |
-3.5% (STABILIZE) |
STABILIZE — initial Archetype C selloff partially recovers, but FY-maintain math limits follow-through |
LOW |